The overall survival benefit of immunotherapy in elderly patients with advanced non-small-cell lung cancer is unclear according to two studies with contradictory results presented at the European Lung Cancer Congress 2019 in Geneva, Switzerland.
Maintenance treatment with nivolumab, either given alone or alongside ipilimumab, does not prolong the overall survival of patients with extensive-stage small-cell lung cancer, the CheckMate 451 investigators have found.
Lorlatinib is more efficacious against non-small-cell lung cancer with versus without ALK resistance mutations in patients with disease progression after at least one second-generation ALK–tyrosine kinase inhibitor, suggests research.
The Multicentric Italian Lung Detection study findings indicate that extending lung cancer screening beyond 5 years boosts the survival benefits associated with early disease detection.
The NILE study has shown the noninferiority of cell-free DNA analysis, so-called liquid biopsy, to the standard of care for identifying targetable biomarkers in individuals with treatment-naïve metastatic non-small-cell lung cancer.
The multikinase inhibitor entrectinib elicits systemic and intracranial responses in patients with locally advanced or metastatic solid tumors harboring NTRK fusions, including those with non-small-cell lung cancer, suggests a pooled analysis of three early-phase clinical trials.
Data from the phase Ib TATTON trial suggest that patients with EGFR-mutated non-small-cell lung cancer who have progressed on prior EGFR–tyrosine kinase inhibitor therapy could benefit from adding either the MET inhibitor savolitinib or the MEK inhibitor selumetinib to osimertinib.
Single-agent pembrolizumab could be a promising option for extensive-stage small-cell lung cancer patients who have received at least two prior lines of therapy, suggests a pooled analysis of data from the multicohort KEYNOTE-028 and -158 trials.
Patients with high-grade neuroendocrine tumors may benefit from combined treatment with the PD-1 inhibitor nivolumab and the anti-CTLA-4 agent ipilimumab, indicate phase II results.
Phase I results reported at the AACR Annual Meeting 2019 in Atlanta, Georgia, USA, point to the potential of a chimeric antigen receptor T-cell therapy directed against mesothelin in patients with malignant pleural disease.
A US chart review has found no increase in the incidence of severe immune-related adverse events among advanced cancer patients who receive an influenza vaccination during the 2 months before or after initiating immune checkpoint inhibitor therapy.
Researchers report that a cancer gene panel called NCC-GP150 may be able to accurately estimate blood tumor mutational burden in patients with non-small-cell lung cancer, and identify those most likely to benefit from immune blockade therapy.
Patients with advanced EGFR mutation-positive non-small-cell lung cancer who receive osimertinib directly after agents targeting PD-1 or PD-L1 may be at increased risk for developing severe immune-related adverse events, suggests a chart review.
A Danish study has found no protective effect of low-dose aspirin taken after diagnosis on prostate cancer-specific mortality, while South Korean research has identified a link between long-term use of the nonsteroidal anti-inflammatory drug and a reduced risk for incident lung cancer.
A tumor mutational burden cutoff of 10 mutations/Mb could help identify advanced non-small-cell lung cancer patients who are most likely to benefit from first-line treatment with nivolumab plus low-dose ipilimumab, report the CheckMate 568 investigators.
Women may be at greater risk than men for experiencing hyperprogression as a response to cancer treatment with immune checkpoint inhibitors, say researchers.